Liver epigenome changes in patients with hepatopulmonary syndrome: A pilot study

PLoS One. 2021 Feb 25;16(2):e0245046. doi: 10.1371/journal.pone.0245046. eCollection 2021.

Abstract

The hepatopulmonary syndrome (HPS) is defined by the presence of pulmonary gas exchange abnormalities due to intrapulmonary vascular dilatations in patients with chronic liver disease. Changes in DNA methylation reflect the genomic variation. Since liver transplant (LT) reverts HPS we hypothesized that it may be associated with specific liver epigenetic changes. Thus, the aim of this study was to investigate the role of the liver epigenome in patients with HPS. We extracted DNA from paraffin embedded liver tissue samples from 10 patients with HPS and 10 age-, sex- and MELD (Model for End-stage Liver Disease)-matched controls. DNA methylation was determined using the 850K array (Illumina). Weighted Gene Co-expression Network Analysis (WGCNA) was used to identify modules related to defining physiologic characteristics of HPS. Only 12 out of the 20 liver biopsies (7 HPS and 5 controls) had sufficient quality to be analyzed. None of the 802,688 DNA probes analyzed in the case control comparison achieved a significant False Discovery Rate (FDR). WGCNA identified 5 co-methylated gene-modules associated to HPS markers, mainly related to nervous and neuroendocrine system, apoptotic processes, gut bacterial translocation, angiogenesis and vascular remodeling ontologies. To conclude, HPS is associated with nervous/neuroendocrine system and vascular remodeling related liver epigenetic changes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apoptosis / genetics
  • Case-Control Studies
  • DNA Methylation / genetics
  • Epigenome / genetics*
  • Epigenomics / methods
  • Female
  • Hepatopulmonary Syndrome / genetics*
  • Hepatopulmonary Syndrome / pathology
  • Humans
  • Liver / metabolism
  • Liver / pathology*
  • Lung / pathology
  • Male
  • Middle Aged
  • Neovascularization, Physiologic / genetics
  • Neuroendocrine Cells / metabolism
  • Pilot Projects
  • Pulmonary Circulation
  • Pulmonary Gas Exchange / physiology
  • Severity of Illness Index
  • Vascular Remodeling / genetics

Grants and funding

Supported by SEPAR (Spanish Thoracic Society) and MENARINI. Nuria Mendoza is supported by the FI grant (Agaur, Generalitat de Catalunya), and Rosa Faner by the ISC-III (CP16/00039).